This brand name is authorized in Lithuania, Romania, United States
The drug MACUGEN contains one active pharmaceutical ingredient (API):
1
Pegaptanib
UNII 3HP012Q0FH - PEGAPTANIB SODIUM
|
Pegaptanib is a pegylated modified oligonucleotide that binds with high specificity and affinity to extracellular Vascular Endothelial Growth Factor (VEGF165) inhibiting its activity. VEGF is a secreted protein that induces angiogenesis, vascular permeability and inflammation, all of which are thought to contribute to the progression of the neovascular (wet) form of AMD. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
MACUGEN Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
S01LA03 | Pegaptanib | S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1029679 |
Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W64998001 |
Country: US | FDA, National Drug Code | Identifier(s): 68782-001 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.